71772-18-4

Upstream product

• 77-78-1 dimethyl sulfate 
• 518-55-8 conidendrin 
• 74861-40-8 (7'S,8R,8'R)-4,7'-dihydroxy-3,3',4'-trimethoxylignano-9,9'-lactone 
• 69232-85-5 4-(3,4-dimethoxybenzyl)-3-(4'-acetoxy-3'-methoxybenzyl)dihydrofuran-2(3H)-one 
• 347359-71-1 (7RS,8R,8'R)-4,4',7-trihydroxy-3,3'-dimethoxylignano-9,9'-lactone 
• 186581-53-3 diazomethane 
• 80287-36-1 α-conidendrin monomethyl ether 
• 21966-92-7 isolariciresinol dimethyl ether 
• 74-88-4 methyl iodide 

Downstream Products

• 78178-26-4 methyl α-conidendrate dimethyl ether 
• 59527-55-8 ditosylisolariciresinol dimethyl ether 
• 78178-23-1 dimesylisolariciresinol dimethyl ether 
• 1403982-14-8 9',9'-diphenyldimethylcyclolariciresinol 
• 1422430-68-9 9',9'-dimethyldimethylcyclolariciresinol 
• 1422430-71-4 9',9'-di(2-naphthyl)dimethylcyclolariciresinol 
• 78178-29-7 α-conidendreic acid dimethyl ester dimethyl ether 
• 1422430-60-1 9',9'-diphenyldimethylretrodendrin 
• 1422430-59-8 C₄₀H₃₈O₆ 
• 1422430-67-8 C₄₀H₃₈O₅ 
• 1428415-59-1 C₄₀H₃₆O₅ 
• 1422430-61-2 9-O-benzyl-9',9'-diphenyldimethylcyclolariciresinol 
• 1422430-62-3 9’-O-methyl-9-O-benzyl-9',9'-diphenyldimethylcyclolariciresinol 
• 1422430-63-4 9’-O-methyl-9',9'-diphenyl-dimethylcyclolariciresinol 

Relevant academic research and scientific papers

Pharmaceutical compositions comprising 8-substituted dibenzylbutyrolactone lignans

Therapeutic compositions comprising at least one 8-substituted-dibenzylbutyrolactone lignan, preferably a lignan is selected from the group of nortrachelogenin, diasteromeric forms of nortrachelogenin, isomeric forms of nortrachelogenin and combinations thereof as well as 8-methylmatairesinol and 8-methyldimethylmatairesinol, for use in a method of treating cancer or a similar condition wherein the growth factor signaling pathway of a mammal is deregulated. The invention also provides therapeutic pharmaceutical combinations comprising a hydroxy-dibenzylbutyrolactone lignan and at least one TRAIL receptor agonist. The hydroxy-dibenzylbutyrolactone lignans and a TRAIL receptor agonist can be used as a combined preparation for administration to a patient simultaneously, separately or spaced out over a period of time in treating cancer.

Synthesis and structural analysis of sterically hindered chiral 1,4-diol ligands derived from the lignan hydroxymatairesinol

The readily available natural lignan hydroxymatairesinol was transformed into sterically hindered and optically pure diphenyl, di-2-naphthyl, and tetramethyl 1,4-diol derivatives via arylation/alkylation of the aryltetralinbutyrolactone lignan (-)-conidendrin. In addition, the diastereoselective formation of stable hemiketals from the highly substituted butyrolactone was studied in detail. The conformations of the molecules prepared were studied computationally at molecular mechanics (MM), Hartree-Fock (HF)/6-31G*, and (DFT/B3LYP/TZVP) levels including entropy contributions and by NMR-spectroscopy. The conformations adopted showed that these novel chiral 1,4-diols may be suitable as chiral ligands for the development of new chiral transition metal and organo catalysts.

Cytotoxic responses to aromatic ring and configurational variations in α-conidendrin, podophyllotoxin, and sikkimotoxin derivatives

Derivatives of α-conidendrin, podophyllotoxin, and sikkimotoxin were prepared to evaluate the cytotoxic contributions of C-4 configuration and pendant and fused arene substitutions. Dimethyl-α-conidendryl alcohol (5), 9-deoxypodophyllol (6), and 9-deoxysikkimol (17) were dehydrated to their respective oxolane derivatives 4, 3, and 9. Diols 5 and 6 were converted via oxabicyclo[3.2.1]octanols 10 and 14 to target oxolanes 8 and 7 where C-4 had been inverted relative to that in 3 and 4. Cytotoxicities of the five oxolanes were determined in two drug-sensitive human leukemia and two multidrug-resistant cell lines expressing P-glycoprotein or multidrug-resistance associated protein (MRP). Changing the pendant arene configuration or replacing a m-methoxy by hydrogen resulted in a 100-fold cytotoxicity loss. Replacing a methylenedioxy group in the fused arene by two methoxy substituents reduced cytotoxicity by 10-fold. Drug-resistant cell lines were equally resistant to compounds 3, 4, 8, and 9 indicating that these four compounds do not serve as substrates of the transport proteins P-glycoprotein and MRP.